Small molecule · Inhibitor of RAS GTPase (KRAS, NRAS, HRAS) (KRAS) · developed by Revolution Medicines
Daraxonrasib is an orally bioavailable RAS inhibitor that binds cyclophilin A and the active, GTP-bound form of wild-type and mutant KRAS, NRAS and HRAS, forming a tri-complex that blocks downstream RAS signaling. It is being studied in pancreatic ductal adenocarcinoma, non-small cell lung cancer, colorectal cancer and other advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 27, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07252232 | Phase 3 | Pancreatic Cancer | Recruiting | RVMD |
| NCT06625320 | Phase 3 | Pancreatic Cancer | Active not recruiting | RVMD |
| NCT07397338 | Phase 1/2 | Advanced Solid Tumors | Recruiting | RVMD |
| NCT06922591 | Phase 1/2 | PDAC | Recruiting | TNGX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsColorectal Cancer (CRC)CRCLung CancerMetastatic Solid TumorsMTAP DeletionNon-small Cell Lung Cancer (NSCLC)NSCLCPancreatic CancerPancreatic Cancer MetastaticPancreatic Ductal Adenocarcinoma (PDAC)PDACPDAC - Pancreatic Ductal AdenocarcinomaRAS Mutation
Updated Nov 8, 2026. Something wrong or missing? Report it on the RVMD page.
See RVMD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RVMD catalysts and pipeline →